IV infusion
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Duchenne Muscular Dystrophy (DMD)
Conditions
Duchenne Muscular Dystrophy (DMD)
Trial Timeline
Dec 17, 2024 → May 28, 2025
NCT ID
NCT06833931About IV infusion
IV infusion is a phase 2 stage product being developed by PepGen for Duchenne Muscular Dystrophy (DMD). The current trial status is withdrawn. This product is registered under clinical trial identifier NCT06833931. Target conditions include Duchenne Muscular Dystrophy (DMD).
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06833931 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Duchenne Muscular Dystrophy (DMD)